ArticleAesthetic surgery journal. Open forum2025
Efficacy of a Mixture of Diosmin, Coumarin, and Arbutin on Preventing Breast Edema in Implant-Based Breast Reconstruction.
Article in Aesthetic surgery journal. Open forum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postmastectomy breast edema is a common complication in patients undergoing immediate implant-based reconstruction, leading to physical and psychological consequences. Despite its clinical relevance, standardized prophylactic strategies remain lacking. Objectives: The authors of this study aim to evaluate the efficacy of an anti-edema formulation containing diosmin, coumarin, and arbutin (Linfadren, Omega Pharma Srl, Italy) in reducing postmastectomy breast edema and improving postoperative outcomes. Methods: A prospective, randomized clinical trial was conducted at a single tertiary care center. Women aged ≥18 years undergoing mastectomy with immediate implant-based reconstruction were randomized (1:1) into 2 groups: control (standard postoperative prophylaxis) and experimental (standard prophylaxis plus Linfadren, Omega Pharma Srl). Mastectomy flap thickness was measured using Vernier calipers, and breast edema symptoms were assessed with the Breast Edema Questionnaire (BrEQ). Follow-up visits were scheduled weekly during the first month, with additional evaluations at 6 weeks and 2 months. Results: The experimental group demonstrated a significant reduction in mastectomy flap thickness (45.95% decrease at 2 months vs stable or increased thickness in the control group, Conclusions: In this study, the authors highlight the potential of Linfadren (Omega Pharma Srl) as an effective prophylactic treatment for postmastectomy breast edema. By mitigating edema, this approach may improve postoperative recovery, reduce complications, and enhance patients' quality of life. Further large-scale studies are warranted to validate these findings. Level of Evidence 2 Therapeutic:
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.